Showing results (11-20 of 342) with videos related to
Sort By:
Pageof 35
Expert Review of Endocrinology & Metabolism|February 10, 2019
Safety and efficacy of velaglucerase alfa replacement therapy for patients with type 1 Gaucher diseaseDeborah Elstein, Ari ZimranInternal Medicine Journal|July 26, 2023
Rapid home therapy infusion of velaglucerase alfa in naïve patients with Gaucher diseaseMichal Becker-Cohen, Shoshana Revel-Vilk, Dafna Frydman, et al.Journal of Clinical Medicine|September 28, 2023
Real-World Experiences with Taliglucerase Alfa Home Infusions for Patients with Gaucher Disease: A Global Cohort StudyShoshana Revel-Vilk, Royston Mansfield, Neta Feder-Krengel, et al.Blood Cells, Molecules & Diseases|November 14, 2019
Gaucher disease, myelodysplastic syndrome and ICUSRosa Ruchlemer, Moshe Mittelman, Ari ZimranImmunology and Cell Biology|June 17, 2009
Glucocerebroside: an evolutionary advantage for patients with Gaucher disease and a new immunomodulatory agentYaron Ilan, Deborah Elstein, Ari ZimranBest Practice & Research. Clinical Endocrinology & Metabolism|May 20, 2015
The emergence of Parkinson disease among patients with Gaucher diseaseDeborah Elstein, Roy Alcalay, Ari ZimranHematology (Amsterdam, Netherlands)|December 12, 2003
Platelet counts and interleukin-6 (IL-6) promoter polymorphism in patients with Gaucher diseaseDeborah Elstein, Gheona Altarescu, Ari ZimranBlood Cells, Molecules & Diseases|May 3, 2006
Increased incidence of Parkinson disease among relatives of patients with Gaucher diseaseAssaf Halperin, Deborah Elstein, Ari ZimranBlood Cells, Molecules & Diseases|June 15, 2010
Nonprecipitous changes upon withdrawal from imiglucerase for Gaucher disease because of a shortage in supplyAri Zimran, Gheona Altarescu, Deborah ElsteinBlood Cells, Molecules & Diseases|October 23, 2012
Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher diseaseAri Zimran, Gheona Altarescu, Deborah ElsteinPageof 35